Deficient metabolism of debrisoquine and sparteine. 1980

T Inaba, and S V Otton, and W Kalow

Genetic deficiencies of alicyclic hydroxylation of debrisoquine and of sparteine oxidation are independently discovered entities, each of clinical significance in its sphere. This paper reports evidence to indicate that these 2 deficiencies have the same cause. Previous investigation of one of the affected subjects had revealed normal oxidative metabolism of amobarbital and antipyrine in terms of both metabolic rates and urinary metabolite patterns. Thus the genetic defect in the metabolism of sparteine and debrisoquine is not a generalized deficiency of drug oxidation or of the cytochrome P450 system.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000654 Amobarbital A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) Amylobarbitone,Pentymal,Amobarbital Sodium,Amsal,Amylbarb sodium,Amylobeta,Amytal,Amytal Sodium,Barbamyl,Eunoctal,Isoamitil Sedante,Isonal,Neur-Amyl,Novamobarb,Placidel,Sodium Amobarbital,Sodium Amytal,Transital,Amobarbital, Sodium,Sodium, Amobarbital
D000983 Antipyrine An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) Phenazone,Anodynin,Pyramidone

Related Publications

T Inaba, and S V Otton, and W Kalow
June 1984, Clinical pharmacology and therapeutics,
T Inaba, and S V Otton, and W Kalow
January 1990, Pharmacology & therapeutics,
T Inaba, and S V Otton, and W Kalow
January 1990, Pharmacology & therapeutics,
T Inaba, and S V Otton, and W Kalow
January 1991, British journal of clinical pharmacology,
T Inaba, and S V Otton, and W Kalow
March 1983, British journal of clinical pharmacology,
T Inaba, and S V Otton, and W Kalow
January 1986, Progress in clinical and biological research,
T Inaba, and S V Otton, and W Kalow
November 1995, Drug metabolism and disposition: the biological fate of chemicals,
T Inaba, and S V Otton, and W Kalow
April 1993, British journal of clinical pharmacology,
T Inaba, and S V Otton, and W Kalow
January 1985, European journal of clinical pharmacology,
T Inaba, and S V Otton, and W Kalow
February 1982, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!